Absci Corporation (ABSI)Healthcare | Biotechnology | Vancouver, United States | NasdaqGS
10.16 USD
+1.22
(13.647%)
⇧
(Oct. 9, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 2:32 a.m. EDT
The investment case here is fractured between aggressive short-term momentum and deteriorating long-term fundamentals. On the short end, the stock is showing signs of a recovery rally, trading significantly above its 200-day average and benefiting from recent analyst upgrades and positive news flow regarding trial data. This has created a 'momentum' narrative where traders are chasing the bounce. However, looking deeper reveals a business in distress: revenue has contracted by nearly half year-over-year, operating margins are deeply negative, and the company is burning cash aggressively. The balance sheet, while currently liquid, is not generating free cash flow to sustain operations without external capital. The options market confirms this skepticism, with investors stacking up cheap insurance (puts) at strikes far below the current price, betting that the rally will stall and the stock will revert to its lower historical values. While the immediate trend is upward, the underlying engine is sputtering, making this a high-risk speculative play rather than a sound investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.084701 |
| MSTL | 0.143738 |
| AutoETS | 0.152646 |
| AutoARIMA | 0.163054 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 4.67 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.492 |
| Excess Kurtosis | -0.55 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.556 |
| Revenue per Share | 0.01 |
| Market Cap | 1,743,598,336 |
| Forward P/E | -15.05 |
| Beta | 2.28 |
| Previous Name | Absci, CORP |
| Website | https://www.absci.com |
As of Oct. 10, 2026, 2:32 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive open interest in deep out-of-the-money puts (strikes at 3.0 and 4.0 for 2028 expiration) compared to negligible call volume at those strikes. While there is some call activity near current prices, the overwhelming capital allocation is in put writing or buying far below the current price, suggesting a fear of a significant correction or a belief that the current valuation is unsustainable.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.7759564 |
| Address1 | 18,105 SE Mill Plain Boulevard |
| All Time High | 31.53 |
| All Time Low | 1.111 |
| Ask | 10.85 |
| Ask Size | 3 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 4,503,400 |
| Average Daily Volume3 Month | 3,441,551 |
| Average Volume | 3,441,551 |
| Average Volume10Days | 4,503,400 |
| Beta | 2.28 |
| Bid | 7.34 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 1.435 |
| City | Vancouver |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 10.16 |
| Current Ratio | 10.627 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,789,430,400 |
| Day High | 10.3902 |
| Day Low | 8.93 |
| Debt To Equity | 1.556 |
| Display Name | Absci |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,480,200 |
| Earnings Call Timestamp Start | 1,786,480,200 |
| Earnings Timestamp | 1,786,478,400 |
| Earnings Timestamp End | 1,794,859,200 |
| Earnings Timestamp Start | 1,794,859,200 |
| Ebitda | -119,506,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -11.589 |
| Enterprise To Revenue | 887.231 |
| Enterprise Value | 1,384,968,192 |
| Eps Current Year | -0.80569 |
| Eps Forward | -0.67516 |
| Eps Trailing Twelve Months | -0.79 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.2622 |
| Fifty Day Average Change | 0.8977995 |
| Fifty Day Average Change Percent | 0.096931554 |
| Fifty Two Week Change Percent | 177.59564 |
| Fifty Two Week High | 12.055 |
| Fifty Two Week High Change | -1.8950005 |
| Fifty Two Week High Change Percent | -0.15719622 |
| Fifty Two Week Low | 2.24 |
| Fifty Two Week Low Change | 7.92 |
| Fifty Two Week Low Change Percent | 3.5357144 |
| Fifty Two Week Range | 2.24 - 12.055 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,626,960,600,000 |
| Float Shares | 163,793,560 |
| Forward Eps | -0.67516 |
| Forward P E | -15.048285 |
| Free Cashflow | -50,591,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 140 |
| Fullday Change | -0.03999996 |
| Fullday Change Percent | -0.39370042 |
| Fullday Price | 10.12 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -84,226,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11842 |
| Held Percent Institutions | 0.87306 |
| Implied Shares Outstanding | 171,614,010 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-22 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington. |
| Long Name | Absci Corporation |
| Market | us_market |
| Market Cap | 1,743,598,336 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_266013918 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-12 |
| Net Income To Common | -121,077,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,672,378,527 |
| Number Of Analyst Opinions | 10 |
| Open | 9.15 |
| Operating Cashflow | -108,084,000 |
| Operating Margins | -107.415085 |
| Overall Risk | 8 |
| Phone | 360 949 1041 |
| Pre Market Change | -0.03999996 |
| Pre Market Change Percent | -0.39370042 |
| Pre Market Price | 10.12 |
| Pre Market Time | 1,791,794,460 |
| Prev Name | Absci, CORP |
| Previous Close | 8.94 |
| Price Eps Current Year | -12.61031 |
| Price Hint | 2 |
| Price To Book | 7.0801396 |
| Price To Sales Trailing12 Months | 1,116.9752 |
| Profit Margins | 0.0 |
| Quick Ratio | 10.263 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.36364 |
| Region | US |
| Regular Market Change | 1.2200003 |
| Regular Market Change Percent | 13.646536 |
| Regular Market Day High | 10.3902 |
| Regular Market Day Low | 8.93 |
| Regular Market Day Range | 8.93 - 10.3902 |
| Regular Market Open | 9.15 |
| Regular Market Previous Close | 8.94 |
| Regular Market Price | 10.16 |
| Regular Market Time | 1,791,576,001 |
| Regular Market Volume | 4,245,312 |
| Return On Assets | -0.34095 |
| Return On Equity | -0.57724 |
| Revenue Growth | -0.464 |
| Revenue Per Share | 0.01 |
| Sand P52 Week Change | 0.17383456 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 171,614,010 |
| Shares Percent Shares Out | 0.2171 |
| Shares Short | 37,255,325 |
| Shares Short Previous Month Date | 1,786,665,600 |
| Shares Short Prior Month | 37,417,586 |
| Short Name | Absci Corporation |
| Short Percent Of Float | 0.2641 |
| Short Ratio | 13.34 |
| Source Interval | 15 |
| State | WA |
| Symbol | ABSI |
| Target High Price | 17.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 14.4 |
| Target Median Price | 15.5 |
| Total Cash | 201,142,000 |
| Total Cash Per Share | 1.172 |
| Total Debt | 3,829,000 |
| Total Revenue | 1,561,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.79 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.025425 |
| Two Hundred Day Average Change | 4.134575 |
| Two Hundred Day Average Change Percent | 0.6861881 |
| Type Disp | Equity |
| Volume | 4,245,312 |
| Website | https://www.absci.com |
| Zip | 98,683 |